尿酸升高不改变骨转换标志物:绝经后女性肌苷补充随机对照试验
OBJECTIVE: Observational studies have consistently demonstrated that serum urate level positively correlates with bone mineral density (BMD).…
要点
- 肌苷补充6个月使绝经后女性血清尿酸持续显著升高。
- 尿酸升高未改变PINP或β-CTX等骨转换标志物水平。
- 两组骨密度及不良事件相似,不支持尿酸直接作用于骨转换。
核心结论
- 肌苷补充虽使绝经后女性血清尿酸持续升高6个月,但未改变骨转换标志物,不支持尿酸对骨转换有直接生物学效应。
主要发现
- 肌苷组血清尿酸在研究期间显著升高,所有随访时间点P<0.0001。
- 第26周肌苷组血清尿酸平均变化为+0.13 mmol/L(+2.2 mg/dl),安慰剂组为0.00 mmol/L(0 mg/dl)。
- 6个月内两组PINP与β-CTX水平无差异,骨密度无显著变化,不良事件与严重不良事件相似。
关键数值与推荐
- 共同主要终点为I型前胶原N端前肽(PINP)水平变化和I型胶原β-C端肽(β-CTX)水平变化。
- 关键排除标准包括骨质疏松、既往脆性骨折、双膦酸盐治疗、痛风、肾结石及尿pH≤5.0。
临床怎么用
- 对于绝经后女性,不应仅基于血清尿酸水平升高来推断骨转换状态或期望通过降尿酸直接改善骨代谢。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Observational studies have consistently demonstrated that serum urate level positively correlates with bone mineral density (BMD). We undertook this study to determine whether moderate hyperuricemia induced by inosine supplements influences bone turnover markers in postmenopausal women over a 6-month period. METHODS: One hundred twenty postmenopausal women were recruited for a 6-month randomized, double-blind, placebo-controlled trial. Key exclusion criteria were osteoporosis, previous fragility fracture, bisphosphonate therapy, gout, kidney stones, and a urine pH level of ≤5.0. Participants were randomized in a 1:1 ratio to receive placebo or inosine. The coprimary end points were change in levels of N-propeptide of type I procollagen (PINP) and change in levels of β-C-telopeptide of type I collagen (β-CTX). Change in BMD, as measured by dual x-ray absorptiometry, was an exploratory end point. RESULTS: Administration of inosine led to a significant increase in serum urate concentration over the study period (P < 0.0001 for all follow-up time points). At week 26, the mean change in serum urate concentration was +0.13 mmoles/liter (+2.2 mg/dl) in the inosine group and 0.00 mmoles/liter (0 mg/dl) in the placebo group. There was no difference in PINP or β-CTX levels between groups over the 6 months. There were no significant changes in bone density between groups over the 6 months. Adverse events and serious adverse events were similar between the 2 groups. CONCLUSION: This clinical trial shows that although inosine supplementation leads to sustained increases in serum urate levels over a 6-month period, it does not alter markers of bone turnover in postmenopausal women. These findings do not support the concept that urate has direct biologic effects on bone turnover.
引用
- Dalbeth N, Horne A, Mihov B, et al. Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. Arthritis Rheumatol. 2021. PMID: 33586367. doi:10.1002/art.41691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。